Related Experiment Video
Updated: Aug 13, 2025
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic
Fred Stephen Sarfo1,2, Michelle Nichols3, Priscilla Abrafi Opare-Addo2
1Department of Medicine, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana (F.S.S.).
Insights
Cardiovascular polypills offer a promising strategy for preventing strokes and atherosclerotic cardiovascular diseases in low- and middle-income countries (LMICs). Research shows significant reductions in stroke risk and cardiovascular events, though real-world effectiveness requires further study.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Health Economics
Background:
- Strokes and atherosclerotic cardiovascular diseases (ASCVD) pose a growing burden in low- and middle-income countries (LMICs).
- Traditional vascular risk factors are increasing in LMICs, exacerbating the challenge.
- Cardiovascular polypills, a single pill combining multiple medications, are a potential solution.
Purpose of the Study:
- To evaluate the effectiveness and cost-effectiveness of cardiovascular polypills for ASCVD prevention in LMICs.
- To identify barriers to polypill adoption in routine clinical practice in LMICs.
Main Methods:
- Analysis of large multicenter trials in LMICs and high-income countries (HICs).
- Review of cost-effectiveness analyses from LMICs.
- Identification of contextual barriers through mixed methods research and hybrid trials.
Main Results:
- Cardiovascular polypills demonstrated a 50% reduction in primary stroke risk compared to placebo or usual care.
- In HICs, polypills reduced major cardiovascular events by 25% in myocardial infarction survivors due to improved adherence.
- Cost-effectiveness analyses suggest potential cost savings in LMICs for both primary and secondary prevention.
Conclusions:
- Cardiovascular polypills are a viable strategy for primary and secondary prevention of ASCVD in LMICs.
- Further research, including mixed methods and hybrid trials, is needed to assess real-world effectiveness and overcome implementation barriers.
- Addressing contextual barriers is crucial for widespread adoption of polypills in routine care.
Abstract:
Current projections are that the already overwhelming burden of strokes and atherosclerotic cardiovascular diseases in low- and middle-income countries (LMICs) will continue to rise over the coming decades as the prevalence of traditional vascular risk factors burgeon in these countries. Cardiovascular polypills containing combinations of antihypertensive(s), a statin, with or without aspirin or folic acid in the form of a single pill, represent a viable strategy for both primary and secondary prevention of atherosclerotic cardiovascular diseases in LMICs. Large multicenter trials in LMIC and high-income country (HIC) settings have now clearly demonstrated the beneficial effects of the cardiovascular polypill versus placebo (or usual care) in reducing primary stroke risk by 50%. For survivors of a recent myocardial infarction residing in HICs, the polypill reduced risk of major cardiovascular events by 25% due to improved treatment adherence. Data on the clinical efficacy of the polypill for secondary stroke prevention are scanty both in HICs and LMICs. Cost-effectiveness analyses data from LMICs suggest cost savings with the polypill for primary and secondary prevention of stroke and atherosclerotic cardiovascular diseases. However, major contextual barriers in LMICs need to be surmounted through mixed methods research and hybrid clinical trials to assess its real-world effectiveness, before the adoption of the polypill for primary and secondary atherosclerotic cardiovascular disease prevention in routine clinical practice.
More Related Videos
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
09:52Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
Published on: January 15, 2017
Related Concept Videos
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
01:26Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
01:30Preventive Healthcare Services